Epidemiology and Prevention Homoarginine, Cardiovascular Risk, and Mortality

Background—Homoarginine is an amino acid derivative that may increase nitric oxide availability and enhance endothelial function. The effect of the level of homoarginine on cardiovascular outcome and mortality is unknown. Methods and Results—We assessed cardiovascular and all-cause mortality according to homoarginine levels in a cohort of 3305 subjects referred for coronary angiography from the LUdwigshafen RIsk and Cardiovascular Health (LURIC) Study. After investigating the relation of homoarginine with kidney function and markers of endothelial dysfunction, we explored its effects on adverse outcomes in a second high-risk cohort of 1244 patients with type 2 diabetes mellitus receiving maintenance hemodialysis (4D study [Die Deutsche Diabetes Dialyse Studie]). In the LURIC study, mean serum homoarginine levels were 2.6 1.1 mol/L. During a median follow-up of 7.7 years, 766 patients died. After adjustments for age and sex, patients in the lowest quartile ( 1.85 mol/L) had a 4-fold higher rate of dying of cardiovascular disease (hazard ratio 4.1, 95% confidence interval 3.0 to 5.7) than patients in the highest quartile ( 3.1 mol/L). Lower homoarginine levels were associated with lower estimated glomerular filtration rate and higher levels of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1. Hemodialysed patients had lower mean homoarginine levels of 1.2 0.5 mol/L and experienced a 5-fold increased mortality rate compared with LURIC patients (608 deaths during a median follow-up of 4 years). Homoarginine consistently affected mortality, which was 2-fold higher in 4D study patients in the lowest quartile ( 0.87 mol/L) than in patients in the highest quartile ( 1.4 mol/L). Conclusions—Homoarginine levels are independently associated with cardiovascular and all-cause mortality in patients referred for coronary angiography and in patients undergoing hemodialysis. Future studies are needed to elucidate the underlying pathomechanisms. (Circulation. 2010;122:967-975.)

[1]  T. Laitinen,et al.  Serum L-homoarginine concentration is elevated during normal pregnancy and is related to flow-mediated vasodilatation. , 2008, Circulation journal : official journal of the Japanese Circulation Society.

[2]  C. Wanner,et al.  A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. , 2008, Kidney international.

[3]  J. Bauersachs,et al.  Endothelial dysfunction in heart failure. , 2008, Pharmacological reports : PR.

[4]  J. Ribalta,et al.  Reference values for plasma concentrations of asymmetrical dimethylarginine (ADMA) and other arginine metabolites in men after validation of a chromatographic method. , 2007, Clinica chimica acta; international journal of clinical chemistry.

[5]  Simon Capewell,et al.  Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. , 2007, The New England journal of medicine.

[6]  W. März,et al.  Asymmetrical dimethylarginine independently predicts total and cardiovascular mortality in individuals with angiographic coronary artery disease (the Ludwigshafen Risk and Cardiovascular Health study). , 2007, Clinical chemistry.

[7]  Zhihong Yang,et al.  Endothelial arginase: A new target in atherosclerosis , 2006, Current hypertension reports.

[8]  J. Chin-Dusting,et al.  AMINO ACIDS, ARGINASE AND NITRIC OXIDE IN VASCULAR HEALTH , 2006, Clinical and experimental pharmacology & physiology.

[9]  H Tunstall-Pedoe,et al.  Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. , 2005, JAMA.

[10]  Peter Libby,et al.  The forgotten majority: unfinished business in cardiovascular risk reduction. , 2005, Journal of the American College of Cardiology.

[11]  W. März,et al.  Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. , 2005, The New England journal of medicine.

[12]  Stanley L Hazen,et al.  Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. , 2005, JAMA.

[13]  W. März,et al.  Randomized Controlled Trial on the Efficacy and Safety of Atorvastatin in Patients with Type 2 Diabetes on Hemodialysis (4D Study): Demographic and Baseline Characteristics , 2004, Kidney and Blood Pressure Research.

[14]  G. Eknoyan,et al.  National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification , 2003, Annals of Internal Medicine.

[15]  R. Nijveldt,et al.  Determination of arginine, asymmetric dimethylarginine, and symmetric dimethylarginine in human plasma and other biological samples by high-performance liquid chromatography. , 2002, Analytical biochemistry.

[16]  W. März,et al.  Rationale and design of the LURIC study--a resource for functional genomics, pharmacogenomics and long-term prognosis of cardiovascular disease. , 2001, Pharmacogenomics.

[17]  I. Lundquist,et al.  Arginine-induced insulin release is decreased and glucagon increased in parallel with islet NO production. , 1998, American journal of physiology. Endocrinology and metabolism.

[18]  P. Ponikowski,et al.  Wasting as independent risk factor for mortality in chronic heart failure , 1997, The Lancet.

[19]  A. Hrabák,et al.  Comparison of substrate and inhibitor specificity of arginase and nitric oxide (NO) synthase for arginine analogues and related compounds in murine and rat macrophages. , 1994, Biochemical and biophysical research communications.

[20]  P. Vallance,et al.  The effect of malnutrition on cardiovascular mortality in dialysis patients: is L-arginine the answer? , 1994, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[21]  Y. Yoshimura,et al.  Sensitivity of intestinal alkaline phosphatase to L-homoarginine and its regulation by subunit-subunit interaction. , 1994, Japanese journal of pharmacology.

[22]  P. Sanders,et al.  Role of nitric oxide synthesis in salt-sensitive hypertension in Dahl/Rapp rats. , 1993, Hypertension.

[23]  H. Erbersdobler,et al.  Homoarginine labeling is suitable for determination of protein absorption in miniature pigs. , 1991, The Journal of nutrition.

[24]  S. Moncada,et al.  An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[25]  Richard Graham Knowles,et al.  Formation of nitric oxide from L-arginine in the central nervous system: a transduction mechanism for stimulation of the soluble guanylate cyclase. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[26]  W. Malaisse,et al.  Stimulus-secretion coupling of arginine-induced insulin release. Uptake of metabolized and nonmetabolized cationic amino acids by pancreatic islets. , 1989, Endocrinology.

[27]  W. Fishman,et al.  L-Homoarginine. An organ-specific, uncompetitive inhibitor of human liver and bone alkaline phosphohydrolases. , 1972, The Journal of biological chemistry.

[28]  R. Johnson,et al.  Homoarginine synthesis by rat kidney. , 1969, Archives of biochemistry and biophysics.

[29]  I. Wells,et al.  Homocitrulline and Homoarginine Synthesis from Lysine , 1964, Science.